Nucleic Acid-Containing Lipid Nanoparticle Patent
Summary
The European Patent Office published Takeda Pharmaceutical Company Limited's patent EP3733211A1 for nucleic acid-containing lipid nanoparticles. The patent covers therapeutic applications including cancer treatment and vaccine technologies, with designated protection across 34 European states. Inventors include Kuwae Shinobu and Matsumoto Satoru.
What changed
The EPO granted Takeda Pharmaceutical patent EP3733211A1 covering nucleic acid-containing lipid nanoparticles and their therapeutic uses. The patent addresses cancer treatments (A61P 35/00) and immunotherapies/vaccines (A61P 37/04), with claims related to CD20-targeting compositions (C07K 16/28) and genetic therapy applications (A61K 48/00, C12N 15/88). The designation covers all EPC contracting states including DE, FR, GB, IT, NL, ES, PL, CH, and others.
Pharmaceutical companies developing mRNA therapeutics, gene therapies, or lipid nanoparticle delivery systems should review this patent for freedom-to-operate implications. Generic drug manufacturers and biotech firms engaged in biosimilar or follow-on product development should assess potential licensing needs. Research institutions conducting related work may need to evaluate patent scope when planning clinical programs or partnerships.
What to do next
- Conduct freedom-to-operate analysis for any lipid nanoparticle products in development
- Review patent claims for potential licensing or design-around opportunities
- Assess patent expiry timeline and generic entry considerations for pipeline products
Archived snapshot
Apr 1, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NUCLEIC ACID-CONTAINING LIPID NANO-PARTICLE AND USE THEREOF
Publication EP3733211A1 Kind: A1 Mar 25, 2026
Applicants
Takeda Pharmaceutical Company Limited
Inventors
KUWAE, Shinobu, MATSUMOTO, Satoru
IPC Classifications
A61K 48/00 20060101AFI20211020BHEP A61K 9/127 20060101ALI20211020BHEP A61K 31/7105 20060101ALI20211020BHEP A61K 31/711 20060101ALI20211020BHEP A61K 47/18 20170101ALI20211020BHEP A61K 47/24 20060101ALI20211020BHEP A61K 47/28 20060101ALI20211020BHEP A61K 47/34 20170101ALI20211020BHEP A61K 47/42 20170101ALI20211020BHEP A61P 35/00 20060101ALI20211020BHEP A61P 37/04 20060101ALI20211020BHEP C07K 14/725 20060101ALI20211020BHEP C07K 16/28 20060101ALI20211020BHEP C12N 5/10 20060101ALI20211020BHEP C12N 15/12 20060101ALI20211020BHEP C12N 15/88 20060101ALI20211020BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.